TriangleNCT01566721 · CITED IN SOURCE DOCUMENTS
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2021-04-27
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period
Percentage of Participants With a Grade 3 or Higher AE During the Treatment Period
Percentage of Participants With Treatment Interruption Due to an AE
Number of Herceptin Cycles Received
Percentage of Participants by Total Number of Herceptin Cycles Received
Percentage of Participants Who Received Concomitant Cancer Therapy
Percentage of Participants Who Received Concomitant Non-Cancer Therapy
Percentage of Participants Who Died by Data Cutoff of 10 March 2015
Percentage of Participants Who Died During the Safety Follow-up Period
Disease-Free Survival Rate
Overall Survival Rate
Percentage of Participants by Item Response to SID Satisfaction Questionnaire
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histologically confirmed early invasive HER2-positive carcinoma of the breast with no evidence of residual, locally recurrent, or metastatic disease and defined as clinical Stage I to IIIC that is eligible for treatment with Herceptin * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Screening left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55% Exclusion Criteria: * Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent * History of other malignancy except for curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or curatively treated malignancies (other than breast cancer) where the participant has been disease-free for at least 5 years * Past history of ductal carcinoma in situ treated with any systemic therapy or with radiation therapy to the ipsilateral breast where invasive cancer subsequently developed * Metastatic disease * Inadequate bone marrow, hepatic, or renal function * Serious cardiac or cardiovascular disease including uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy * History of severe allergic or immunological reactions, such as difficult-to-control asthma * Pregnant or lactating women
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
- intervention Names
- Drug: Herceptin
- label
- Cohort A: SC Herceptin by Needle/Syringe
- type
- EXPERIMENTAL
- description
- Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
- intervention Names
- Drug: Herceptin
- label
- Cohort B: SC Herceptin by SID
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Cohort A: SC Herceptin by Needle/Syringe
- Cohort B: SC Herceptin by SID
- description
- Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
- name
- Herceptin
- other Names
- Trastuzumab
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 2577
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Participants were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported.
- measure
- Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period
- time Frame
- From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)
- description
- Participants were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. AEs were graded according to National Cancer Institute Common Terminology Criteria Version 4.0. Grade 3 AEs were those considered severe or medically significant but not immediately life-threatening. Grade 4 AEs were those considered life-threatening and/or for which urgent intervention was indicated. Grade 5 AEs were those resulting in death. The percentage of participants with a Grade 3 or higher (i.e., Grade 3 to 5) AE during the treatment period was reported.
- measure
- Percentage of Participants With a Grade 3 or Higher AE During the Treatment Period
- time Frame
- From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)
- description
- Participants were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. The percentage of participants with SC Herceptin treatment interrupted to assess or treat AEs was reported.
- measure
- Percentage of Participants With Treatment Interruption Due to an AE
- time Frame
- From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)
- description
- Participants were planned to receive a total of 18 cycles of SC Herceptin. The median number of cycles actually received was reported.
- measure
- Number of Herceptin Cycles Received
- time Frame
- From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)
- description
- Participants were planned to receive a total of 18 cycles of SC Herceptin. The percentage of participants was reported by the total number of cycles actually received. Because the data are presented non-cumulatively, this table reflects participant distribution by the highest number of cycles received.
- measure
- Percentage of Participants by Total Number of Herceptin Cycles Received
- time Frame
- From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)
- description
- Concomitant cancer treatment included chemotherapy, radiotherapy, and hormone therapy administered during the study. The percentage of participants who received any of these concomitant therapies was reported.
- measure
- Percentage of Participants Who Received Concomitant Cancer Therapy
- time Frame
- From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)
- description
- Concomitant non-cancer treatment included any pharmacologic interventions administered during the study other than chemotherapy, radiotherapy, or hormone therapy. The percentage of participants who received any concomitant non-cancer therapies was reported.
- measure
- Percentage of Participants Who Received Concomitant Non-Cancer Therapy
- time Frame
- From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)
- secondary Outcomes
- description
- The percentage of participants who died from any cause was reported.
- measure
- Percentage of Participants Who Died by Data Cutoff of 10 March 2015
- time Frame
- From Baseline to time of event (maximum follow-up approximately 3 years as of data cutoff of 10 March 2015)
- description
- The percentage of participants who died from any cause was reported during the safety follow-up period.
- measure
- Percentage of Participants Who Died During the Safety Follow-up Period
- time Frame
- From Baseline to Time of Event, Safety Follow-Up Period (Up to 6 Years)
- description
- DFS is defined as the time from first dose of SC Herceptin to the first event of local, regional or distant recurrence, contralateral invasive breast cancer (including ipsilateral ductal carcinoma in situ) or death due to any cause. Time from the date of first dose to any DFS event was expressed in Kaplan-Meier survival probability estimates. Patients without an event will be censored at the last assessment date.
- measure
- Disease-Free Survival Rate
- time Frame
- From Baseline to time of event (up to approximately 8 years)
- description
- Overall survival was defined as the time from randomization to death from any cause. Time from the date of randomization to the date of death was expressed in Kaplan-Meier survival probability estimates. Patients without an event will be censored at the last assessment date.
- measure
- Overall Survival Rate
- time Frame
- From Baseline to Time of Event (Up to Approximately 6 Years)
- description
- The SID satisfaction questionnaire was administered twice during the study and asked participants to respond to five statements using a Likert scale from "Strongly Disagree" to "Strongly Agree". Questionnaire items were as follows: "I felt comfortable injecting the study drug by myself" (Comfortable), "The SID was convenient and easy to use" (Easy to Use), "I am confident giving myself an injection in the thigh with the SID" (Confident), "Taking all things into account I find self-administration using the SID satisfactory" (Satisfactory), "If given the opportunity I would choose to continue self-injecting the study drug using the SID in the future" (Continue). Participants could only select one response per questionnaire item. There was no calculation of any score, but rather, descriptive summaries were generated by item response. The percentage of participants was reported by the response given for each item on the SID satisfaction questionnaire.
- measure
- Percentage of Participants by Item Response to SID Satisfaction Questionnaire
- time Frame
- Cycle 4 (cycle length 3 weeks) and last safety follow-up (LSFU) (approximately 1 year)
Full study description
- brief Summary
- This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).
Source references
- references
- citation
- Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA. Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. Oncologist. 2018 Oct;23(10):1137-1143. doi: 10.1634/theoncologist.2018-0065. Epub 2018 Jul 17.
- pmid
- 30018134
- type
- DERIVED
- citation
- Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.
- pmid
- 28625777
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-ab1dd1ad09b4ebff61fc
- requested nct id
- NCT01566721
- primary nct id
- NCT01566721
- source kind
- fda_spl_label
- source record id
- bdc7c85f-c38e-493d-90c8-105bef6212a9
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- fbae49b09d7d21f27230b923a8b4b3c1fbed59db0849371ecfac3cfe4cb19ac1
- payload
- application numbers
- BLA761106
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-ab1dd1ad09b4ebff61fc
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01566721
- occurrences
- context exact
- S was observed in the final analysis between patients who received intravenous trastuzumab and those who received HERCEPTIN HYLECTA. SafeHER The SafeHER study (NCT01566721) was a prospective, two-cohort, non-randomized, multinational, open-label study designed to assess the overall safety and tolerability of HERCEPTIN HYLECTA wit
- end
- 2541
- exact text
- NCT01566721
- start
- 2530
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/38/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- bdc7c85f-c38e-493d-90c8-105bef6212a9
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3a4f46d69f6ac5278581b8102950c20fc7cb03aa60423e7fa293e886e835ec5c
- spl effective time
- 20260529
- spl set id
- ebf30894-41cf-480c-8bc3-56f592a13813
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-d7f7c7dda3e3ca0adee8
- requested nct id
- NCT01566721
- primary nct id
- NCT01566721
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- payload sha256
- e666b30b462222cf0c3c684fc416a8fc3260b5ee4b026b3eba9d76837658d89c
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-d7f7c7dda3e3ca0adee8
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01566721
- occurrences
- context exact
- 1" tabindex="-1">A subcutaneous (SQ) formulation of trastuzumab has also been approved.</p> <p id="_3192" tabindex="-1">The <a href="/clinicaltrials/NCT01566721">SafeHer</a> trial (NCT01566721) evaluated the safety and tolerability of self-administered versus clinician-administered SQ trastuzumab in patients with stage
- end
- 401617
- exact text
- NCT01566721
- start
- 401606
- context exact
- (SQ) formulation of trastuzumab has also been approved.</p> <p id="_3192" tabindex="-1">The <a href="/clinicaltrials/NCT01566721">SafeHer</a> trial (NCT01566721) evaluated the safety and tolerability of self-administered versus clinician-administered SQ trastuzumab in patients with stage I to stage III HER2-positive br
- end
- 401649
- exact text
- NCT01566721
- start
- 401638
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:35.419733+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
- source title
- Breast Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 25, 2025
- datetime
- 2025-04-25T12:00:00Z
- display
- April 25, 2025
Preserved source evidence · Not medical advice